plant-based ‘COVID-19’ vaccine / G+Flas Life Sci - LARVOL DELTA

Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines. (PubMed, Vaccines (Basel)) - "The potential of a plant-based system for rapid production at a commercial scale and for a quick response to an infectious disease outbreak has been demonstrated by the marketing of carrot-cell-produced taliglucerase alfa (Elelyso) for Gaucher disease and tobacco-produced monoclonal antibodies (ZMapp) for the 2014 Ebola outbreak. The clinical trial of the CoVLP vaccine could be concluded by the end of 2021, and the vaccine could be available for public immunization thereafter. This review encapsulates the efforts made in plant-based COVID-19 vaccine development, the strategies and technologies implemented, and the progress accomplished in clinical trials and preclinical studies so far."

Journal • Review • Gaucher Disease • Genetic Disorders • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases

Plant-Expressed Receptor Binding Domain of the SARS-CoV-2 Spike Protein Elicits Humoral Immunity in Mice. (PubMed, Vaccines (Basel)) - "The current 15-month coronavirus disease-19 (COVID-19) pandemic caused by SARS-CoV-2 has accounted for 3.77 million deaths and enormous worldwide social and economic losses...These findings provide a strong foundation to further advance the development of plant-expressed RBD antigens for use as an effective, safe, and inexpensive SARS-CoV-2 vaccine. Moreover, our study further highlights the utility of plant species for vaccine development."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases